Biogen Revenue 2010-2022 | BIIB
Biogen annual/quarterly revenue history and growth rate from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Biogen revenue for the quarter ending September 30, 2022 was $2.509B, a 9.73% decline year-over-year.
- Biogen revenue for the twelve months ending September 30, 2022 was $10.363B, a 6.64% decline year-over-year.
- Biogen annual revenue for 2021 was $10.982B, a 18.32% decline from 2020.
- Biogen annual revenue for 2020 was $13.445B, a 6.49% decline from 2019.
- Biogen annual revenue for 2019 was $14.378B, a 6.88% increase from 2018.
Biogen Annual Revenue
(Millions of US $) |
| 2021 |
$10,982 |
| 2020 |
$13,445 |
| 2019 |
$14,378 |
| 2018 |
$13,453 |
| 2017 |
$12,274 |
| 2016 |
$11,449 |
| 2015 |
$10,764 |
| 2014 |
$9,703 |
| 2013 |
$6,932 |
| 2012 |
$5,516 |
| 2011 |
$5,049 |
| 2010 |
$4,716 |
| 2009 |
$4,377 |
Biogen Quarterly Revenue
(Millions of US $) |
| 2022-09-30 |
$2,509 |
| 2022-06-30 |
$2,589 |
| 2022-03-31 |
$2,532 |
| 2021-12-31 |
$2,734 |
| 2021-09-30 |
$2,779 |
| 2021-06-30 |
$2,775 |
| 2021-03-31 |
$2,694 |
| 2020-12-31 |
$2,853 |
| 2020-09-30 |
$3,376 |
| 2020-06-30 |
$3,682 |
| 2020-03-31 |
$3,534 |
| 2019-12-31 |
$3,671 |
| 2019-09-30 |
$3,600 |
| 2019-06-30 |
$3,617 |
| 2019-03-31 |
$3,490 |
| 2018-12-31 |
$3,526 |
| 2018-09-30 |
$3,439 |
| 2018-06-30 |
$3,357 |
| 2018-03-31 |
$3,131 |
| 2017-12-31 |
$3,307 |
| 2017-09-30 |
$3,078 |
| 2017-06-30 |
$3,078 |
| 2017-03-31 |
$2,811 |
| 2016-12-31 |
$2,872 |
| 2016-09-30 |
$2,956 |
| 2016-06-30 |
$2,894 |
| 2016-03-31 |
$2,727 |
| 2015-12-31 |
$2,839 |
| 2015-09-30 |
$2,778 |
| 2015-06-30 |
$2,592 |
| 2015-03-31 |
$2,555 |
| 2014-12-31 |
$2,641 |
| 2014-09-30 |
$2,511 |
| 2014-06-30 |
$2,421 |
| 2014-03-31 |
$2,130 |
| 2013-12-31 |
$1,966 |
| 2013-09-30 |
$1,828 |
| 2013-06-30 |
$1,723 |
| 2013-03-31 |
$1,415 |
| 2012-12-31 |
$1,418 |
| 2012-09-30 |
$1,386 |
| 2012-06-30 |
$1,421 |
| 2012-03-31 |
$1,292 |
| 2011-12-31 |
$1,327 |
| 2011-09-30 |
$1,310 |
| 2011-06-30 |
$1,209 |
| 2011-03-31 |
$1,203 |
| 2010-12-31 |
$1,219 |
| 2010-09-30 |
$1,176 |
| 2010-06-30 |
$1,213 |
| 2010-03-31 |
$1,109 |
| 2009-12-31 |
$1,127 |
| 2009-09-30 |
$1,121 |
| 2009-06-30 |
$1,093 |
| 2009-03-31 |
$1,036 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$42.097B |
$10.982B |
|
Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
|
